secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0000950170-22-003666
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reports Q4 2021 net loss of $12.4M; cash $175.3M; pipeline updates on RLYB212 and RLYB116
--------------------------------------------------------------------------------

- Net loss of $12.4M ($0.42 per share) for Q4 2021; full year net loss $47.0M ($1.84 per share).
- Cash and cash equivalents of $175.3M as of December 31, 2021.
- R&D expenses $6.1M in Q4 2021 ($26.9M FY); G&A $6.2M Q4 ($18.7M FY).
- Phase 1b proof-of-concept for RLYB212 (FNAIT) to start Q2 2022; initial data expected Q3 2022.
- Phase 1 study of RLYB116 (C5 inhibitor) initiated; single dose safety/PK/PD data expected 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022003666/0000950170-22-003666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022003666/rlyb-20220315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer